Penny Stock Trading Near Rs 2/Share Hits Upper Circuit After Announcing Record Date For 1:2 Stock Split

Murae Organisor Ltd. (earlier called Earum Pharmaceuticals Ltd.) witnessed a 5% upper circuit on Monday after the company announced the record date for its contemplated stock split. On Monday, the shares of Murae Organisor ended at a 5% upper circuit limit at Rs 1.86 per share with a market cap of Rs 171.95Cr.

In a filing with the exchange on May 30, the company notified the public that the record date for the sub-division of equity shares is slated for Wednesday, June 11, 2025. There will be a two-for-one split of equity shares of Rs 2 of face value held by the shareholders as per the approval granted on May 29, 2025, via a postal ballot.

"As reported in this regard, Murae Organisor Limited has fixed Wednesday, June 11, 2025, as the 'Record Date' for the sub-division (stock split) of every one equity share of face value Rs 2 into two equity shares of Rs 1 each," the company elaborated in its filing.

The acquisition is in-line with the organizational strategy the company has been following of late. Earlier, Murae Organisor announced plans to purchase agricultural land in Kutch Gujarat which is a region deemed important for future industrial and agro based development initiatives. The proposed investment is planned between Rs 20 - 25 crore pending further due diligence and regulatory approvals.

In line with organizational diversification strategy, Murae Organisor has plans to construct a high tech distillery on the purchased land. This investment makes the company participate in the value added industrial products market. This increment of the company into an underserved market is likely to provide access to superior margins and long term sustained growth.

Having started its operations in 2012, Murae Organisor Ltd. has marked notable achievements in the marketing and distributing sectors of medicines. Currently, the company sells over 120 units of \sub-brands such as HYGNEX+, Erolon, and Calcybar, which are multi-national entities versed in brand-name formulations. These products are manufactured by third party suppliers. The catalogue of Murae encompasses antibiotics, antihistamines, analgesics, neurological and dermatological medicines alongside calcium and multivitamin dietary supplements.

By providing further pro-corporate moves through business actions, Murae Organisor Ltd. hopes to transform into an emerging and dynamic body venture in the pharmaceutical industry with its diversification roadmap.